What is PHVS stock price today?

PHVS (Pharvaris Nv) stock is trading at $30.16 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is PHVS stock going up or down today?

PHVS stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy PHVS stock now?

The decision to buy PHVS depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is PHVS a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for PHVS based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is PHVS stock overvalued or undervalued?

Use our DCF valuation calculator to determine if PHVS is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is PHVS's P/E ratio?

P/E ratio data for PHVS will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is PHVS's market cap?

PHVS (Pharvaris Nv) has a market capitalization of $2.11 billion, making it a small-cap stock.

What is PHVS's price to book ratio?

PHVS trades at a price-to-book (P/B) ratio of 7.66, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does PHVS pay dividends?

PHVS does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is PHVS's dividend yield?

PHVS does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is PHVS stock a good long-term investment?

PHVS's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is PHVS's revenue growth rate?

Revenue growth data for PHVS is available on our dashboard with detailed financial statement analysis.

Profitability metrics for PHVS are available on our dashboard with complete income statement analysis.

What are the risks of investing in PHVS?

Key risks for PHVS include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does PHVS compare to its competitors?

Compare PHVS to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize PHVS's performance and positioning.

What is PHVS's stock price target for 2026?

Our AI model provides price targets for PHVS based on fundamental analysis: Bull case $39.21 (+30%), Base case $34.68 (+15%), Bear case $27.14 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about PHVS?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for PHVS. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is PHVS's next earnings report?

PHVS reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

PHVS - Pharvaris Nv

NYSE * Health Care * Biotechnology

$30.16

+$0.30 (+1.00%)

About Pharvaris Nv

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

PHVS Key Statistics

Market Cap

$2.11B

P/B Ratio

7.66

EPS

$-3.16

Employees

134

How PHVS Compares to Peers

PHVS is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
PHVS(This stock)	$2.11B	N/A	0%	0.0%	-
AMGNAmgen Inc	$181.77B	23.4	0%	0.2%	vs AMGN
GILDGilead Sciences	$166.90B	18.3	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$113.59B	26.5	0%	0.4%	vs VRTX
REGNRegeneron Pharmaceuticals	$64.45B	15.0	0%	0.3%	vs REGN
BIIBBiogen Inc	$28.94B	21.1	0%	0.1%	vs BIIB

Pharvaris Nv Company Information

Headquarters: Netherlands
Website: pharvaris.com
Sector: Health Care
Industry: Biotechnology

Data Updated: June 1, 2026 at 11:10 AM EDT

Ready to invest in PHVS?

Commission-free trading available. Affiliate links.

Upcoming Events for PHVS

Dashboard

Enter a ticker to analyze